FIELD: medicine; pharmaceutics.
SUBSTANCE: group of inventions relates to pharmaceutics and medicine. Object 1 is an immune composition for preventing or treating coronavirus infection caused by SARS-CoV-2, containing antigen obtained from coronavirus, polyriboinosinic-polyribocytidylic acid (PIC), kanamycin, calcium chloride, sodium chloride and phosphate buffer solution. Object 2: use of immune composition for preparing a vaccine or drug for preventing or treating coronavirus infection caused by SARS-CoV-2.
EFFECT: increasing the concentration of cytokines in the lungs, activating the dendritic cells of the body for enhancing the regulation of co-stimulating molecules, inducing the production of IgG antibodies, inducing the production of neutralizing antibodies, induction of production of coronavirus-specific cellular immunoreaction, reduction of coronavirus load for prevention or treatment of coronavirus infection caused by SARS-CoV-2.
7 cl, 8 dwg, 15 tbl, 16 ex
Title | Year | Author | Number |
---|---|---|---|
WHOLE VIRION INACTIVATED VACCINE AGAINST SARS-Cov-2 INFECTION AND ITS USE | 2023 |
|
RU2809375C1 |
METHOD OF OBTAINING INACTIVATED VACCINE AGAINST COVID-19 AND VACCINE OBTAINED BY METHOD | 2023 |
|
RU2810740C1 |
COVID-19 VACCINE COMPOSITION | 2021 |
|
RU2766292C1 |
COMPLEX FOR ENHANCING IMMUNE RESPONSE | 2019 |
|
RU2779622C2 |
METHODS OF TREATING CORONAVIRUS INFECTIONS | 2021 |
|
RU2825648C1 |
IMMUNOGENIC MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS (MERS-CoV) COMPOSITIONS AND METHODS | 2014 |
|
RU2685185C2 |
PEPTIDE IMMUNOGENS AND A VACCINE COMPOSITION AGAINST CORONAVIRUS INFECTION COVID-19 USING PEPTIDE IMMUNOGENS | 2020 |
|
RU2738081C1 |
METHOD FOR QUANTITATIVE DETERMINATION OF CONCENTRATION OF S-ANTIGEN IN WHOLE-VIRION INACTIVATED ADSORBED ON ALUMINUM HYDROXIDE, SUBUNIT BASED ON S-PROTEIN, RECOMBINANT OR POLYPEPTIDE, CONTAINING RBD DOMAIN OF SPIKE PROTEIN OF SARS-COV VIRUS FOR PREVENTION OF CORONAVIRUS INFECTION COVID-19 AND/OR OTHER CORONAVIRUS INFECTIONS | 2023 |
|
RU2825291C1 |
PROTEIN AND VACCINE AGAINST SARS-CoV-2 INFECTION | 2020 |
|
RU2815060C1 |
PEPTIDE IMMUNOGENS AND VACCINE COMPOSITION AGAINST COVID-19 WITH THE USE OF PEPTIDE IMMUNOGENS | 2020 |
|
RU2743593C1 |
Authors
Dates
2024-08-08—Published
2021-05-26—Filed